The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Inhibition of human IAPP fibril formation does not prevent β-cell death: evidence for distinct actions of oligomers and fibrils of human IAPP
Abstract
Type 2 diabetes mellitus (T2DM) is characterized by an ∼60% deficit in β-cell mass, increased β-cell apoptosis, and islet amyloid derived from islet amyloid polypeptide (IAPP). Human IAPP (hIAPP) forms oligomers, leading to either amyloid fibrils or toxic oligomers in an aqueous solution in vitro. Either application of hIAPP on or overexpression of hIAPP in cells induces apoptosis. It remains controversial whether the fibrils or smaller toxic oligomers induce β-cell apoptosis. Rifampicin prevents hIAPP amyloid fibril formation and has been proposed as a potential target for prevention of T2DM. We examined the actions of rifampicin on hIAPP amyloid fibril and toxic oligomer formation as well as its ability to protect β-cells from either application of hIAPP or endogenous overexpression of hIAPP (transgenic rats and adenovirus-transduced β-cells). We report that rifampicin (Acocella G. Clin Pharmacokinet 3: 108–127, 1978) prevents hIAPP fibril formation, but not formation of toxic hIAPP oligomers (Bates G. Lancet 361: 1642–1644, 2003), and does not protect β-cells from apoptosis induced by either overexpression or application of hIAPP. These data emphasize that toxic hIAPP oligomers, rather than hIAPP fibrils, initiate β-cell apoptosis and that screening tools to identify inhibitors of amyloid fibril formation are likely to be less useful than those that identify inhibitors of toxic oligomer formation. Finally, rifampicin and related molecules do not appear to be useful as candidates for prevention of T2DM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis
Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W., & Glabe, C. G. (2003) · Science · doi:10.1126/science.1079469 · Cited by 4,064
β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes
Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A., & Butler, P. C. (2003) · Diabetes · doi:10.2337/diabetes.52.1.102 · Cited by 4,011
Self-citationIwai, A., Masliah, E., Yoshimoto, M., Ge, N., Flanagan, L., Rohan de Silva, H. A., Kittel, A., & Saitoh, T. (1995) · Neuron · doi:10.1016/0896-6273(95)90302-x · Cited by 1,316
Cooper, G. J., Willis, A. C., Clark, A., Turner, R. C., Sim, R. B., & Reid, K. B. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.23.8628 · Cited by 1,299 · cited 1×
“Islet amyloid is derived from islet amyloid polypeptide (IAPP), a 37-amino acid protein that is cosecreted along with insulin from pancreatic -cells (8, 35).”
BackgroundIslet amyloid: a long-recognized but underappreciated pathological feature of type 2 diabetes.
Kahn, S. E., Andrikopoulos, S., & Verchere, C. B. (1999) · Diabetes · doi:10.2337/diabetes.48.2.241 · Cited by 488
Butler, A. E., Janson, J., Soeller, W. C., & Butler, P. C. (2003) · Diabetes · doi:10.2337/diabetes.52.9.2304 · Cited by 411
Self-citationOpie, E. L. (1901) · Journal of Experimental Medicine · doi:10.1084/jem.5.5.527 · Cited by 305
Verchere, C. B., D'Alessio, D. A., Palmiter, R. D., Weir, G. C., Bonner-Weir, S., Baskin, D. G., & Kahn, S. E. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.8.3492 · Cited by 278
Replication Increases β-Cell Vulnerability to Human Islet Amyloid Polypeptide-Induced Apoptosis
Ritzel, R. A., & Butler, P. C. (2003) · Diabetes · doi:10.2337/diabetes.52.7.1701 · Cited by 115
Self-citation
Cited by
Bernstein, S. L., Dupuis, N. F., Lazo, N. D., Wyttenbach, T., Condron, M. M., Bitan, G., Teplow, D. B., Shea, J.-E., Ruotolo, B. T., Robinson, C. V., et al. (2009) · Nature Chemistry · doi:10.1038/nchem.247 · Cited by 918
Islet Amyloid in Type 2 Diabetes, and the Toxic Oligomer Hypothesis
Haataja, L., Gurlo, T., Huang, C. J., & Butler, P. C. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0037 · Cited by 612
Self-citationLuca, S., Yau, W.-M., Leapman, R., & Tycko, R. (2007) · Biochemistry · doi:10.1021/bi701427q · Cited by 578
Membrane damage by human islet amyloid polypeptide through fibril growth at the membrane
Engel, M. F. M., Khemtémourian, L., Kleijer, C. C., Meeldijk, H. J. D., Jacobs, J., Verkleij, A. J., de Kruijff, B., Killian, J. A., & Höppener, J. W. M. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708354105 · Cited by 466
Molecular Mechanisms of Amyloid Oligomers Toxicity
Kayed, R., & Lasagna-Reeves, C. A. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-129001 · Cited by 415
Self-citation
Metadata
- Authors
- Meier, J. J., Kayed, R., Lin, C.-Y., Gurlo, T., Haataja, L., Jayasinghe, S., Langen, R., Glabe, C. G., & Butler, P. C.
- Venue
- American Journal of Physiology-Endocrinology and Metabolism
- Publisher
- American Physiological Society
- Published
- 2006-12
- Volume
- 291
- Issue
- 6
- Pages
- E1317-E1324
- ISSN
- 0193-1849 (ISSN-L)
- 1522-1555
- OpenAlex
- W2126160318
- Cited by
- 166
- References
- 9
- FWCI
- 14.34
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.